Louai  Alsaloumi,Shaima  Shawagfeh,Bilgen  Başgut,
Hand and Foot Syndrome Associated with Capecitabine
Annals of Clinical Oncology
2020
2674-3248
http://dx.doi.org/10.31487/j.ACO.2020.02.03
https://www.sciencerepository.org/hand-and-foot-syndrome-associated-with-capecitabine_ACO-2020-2-103 
Abstract: Having cancer impacts the patient both psychologically and physically. However, if cancer is accompanied
with HFS, the patient’s condition gets even worse. Capecitabine is a prodrug approved to treat several types
of cancer such as breast and colorectal cancer. It is associated with several adverse effects such as hand and
foot syndrome (HFS) which mostly affects the palms and legs. The provoked mechanisms of HFS are not
clear yet. They require further validation of HFS pathogenesis. Up to now, prevention and treatment of HFS
are not clearly solidified. Evidence supports the use of celecoxib, urea-based creams, and vitamin E to
reduce the severity and the incidence of HFS. This review aims to provide the gaps and ways to further
clinical evaluations.Keywords: Capecitabine, hand and foot syndrome, palmar-plantar erythrodysesthesia, celecoxib, pyridoxine